Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: A cross-sectional study and the effects of lisinopril

Diabetic Medicine

Volumn 27, Issue 10, 2010, Pages 1144-1150

  Nielsen, S E ^a   Schjoedt, K J ^a   Astrup, A S ^a   Tarnow, L ^a   Lajer, M ^a   Hansen, P R ^a   Parving, H H ^b,c   Rossing, P ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

ACE inhibition; albuminuria; diabetes mellitus; nephrology; tubular damage

Indexed keywords

KIDNEY INJURY MOLECULE 1; LISINOPRIL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PROTEIN URINE LEVEL; RENAL PROTECTION;

ACUTE-PHASE PROTEINS; ALBUMINURIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; LIPOCALINS; LISINOPRIL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS;

EID: 77956855578     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03083.x     Document Type: Article

References (30)

1. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In : Brenner BM, ed. Brenner & Rector's The Kidney. 8th edition. Boston : WB Saunders, 2008 : 1265 1298.
2. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006 69 : 440 449.
3. Brocco E, Fioretto P, Mauer SM, Saller A, Carraro A, Frigato F et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int 1997 63 : S40 S44.
4. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999 56 : 1627 1637.
5. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving H-H, Rossing P. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care in press.
6. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009 32 : 1684 1688.
7. Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β, but not by TNF-α. J Immunol 2003 171 : 6630 6639.
8. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008 52 : 595 605.
9. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006 21 : 856 863.
10. Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007 22 : 101 108.
11. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van GH, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007 212 : 209 217.
12. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002 62 : 237 244.
13. Schjoedt KJ, Astrup AS, Persson F, Frandsen E, Boomsma F, Rossing K et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2009 52 : 46 49.
14. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008 19 : 1283 1290.
15. Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995 26 : 904 909.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med 2006 145 : 247 254.
17. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006 54 : 2577 2584.
18. Wagener G, Lee HT. In reply to 'Instability of urinary NGAL during long-term storage' and 'NGAL and cardiac surgery-associated acute kidney injury'. Am J Kidney Dis 2009 53 : 566.
19. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009 32 : 91 98.
20. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009 75 : 285 294.
21. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004 24 : 307 315.
22. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997 131 : 79 84.
23. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009 32 : 91 98.
24. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009 32 : 91 98.
25. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2006 103 : 1834 1839.
26. Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D et al. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 2009 76 : 395 403.
27. Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. 4th-9th Nov 2008, American Soc of Nephr Philadelphia, USA 2009 24 : 3265 3268.
28. Vaidya VS, Niewczas M, Ficociello LH, Collings FB, Walker W, Harram JH et al. Markers of tubular injury, NAG and KIM-1, are predictors for remission and progression of microalbuminuria in type 1 diabetes. American Society of Nephrology 2008.
29. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002 61 : 31 39.
30. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009 32 : 91 98.